TBPH News

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:TBPH) DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday,...

September 2, 2025Conference

Theravance, Mylan Reach Settlement With Eugia Over YUPELRI ANDA Patent Litigation

TBPH

June 6, 2025

Theravance Biopharma Presents Analyses Of Previous Phase 3 Program Evaluating Ampreloxetine For Treatment Of Symptomatic nOH At International MSA Congress

TBPH

May 9, 2025

Theravance Biopharma Q1 EPS $(0.27) Misses $(0.23) Estimate, Sales $15.39M Miss $15.50M Estimate

TBPH

May 8, 2025

Theravance To Present New Analyses Of Initial Phase 3 Program Of Ampreloxetine Supporting Selective And Differentiated Pharmacodynamic Profile At AAN Meeting

TBPH

March 27, 2025

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

TBPH

February 27, 2025

Theravance Biopharma Q4 Adj EPS $(0.05) Beats $(0.21) Estimate, Sales $18.75M Beat $17.09M Estimate

TBPH

February 26, 2025

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

TBPH

February 25, 2025

Theravance Biopharma's Earnings Outlook

TBPH

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.11.

May 4, 2022